Experimental drug aims to heal damaged lung arteries
NCT ID NCT07487441
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test whether the drug sotatercept can reverse damage to the lung's blood vessels in people with pulmonary arterial hypertension (PAH). Researchers will use special imaging techniques to look inside the arteries and see if they become healthier over 9 months. The study plans to enroll 30 adults with PAH.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sotatercept
What this could lead to
If it works, this could point toward a treatment that reverses lung artery damage in pulmonary hypertension, potentially improving blood flow and symptoms.
What could go wrong
This is a small, early-stage study with only 30 participants. It is not yet recruiting, and the main goal is to see if the drug changes blood vessel structure, not to prove it improves outcomes. There may be risks from the imaging procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Clinical and Translational Sciences Research Center
Tucson, Arizona, 85724, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••